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Abstract: 
 
Objectives: To evaluate determinants of discordance between DAS28-ESR and DAS28-CRP and resulting impact 
on disease activity stratification in rheumatoid arthritis (RA) 
 
Methods: Paired DAS28-ESR and DAS28-CRP readings (n=31,074) were obtained from the British Society for 
Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA). Factors influencing discordance between 
DAS28-ESR and DAS28-CRP were evaluated alongside the resulting effect on disease activity stratification. The 
impact of gender adjustment to the DAS28-CRP was evaluated.  
 
Results: DAS28-CRP scores were ~0.3 lower than DAS28-ESR overall, with greatest differences for women (-0.35) 
and patients over 50 years old (-0.34). Mean male DAS28-CRP scores were 0.15 less than corresponding DAS28-
ESR scores. Discordance between DAS28-ESR and DAS28-CRP significantly impacted disease activity stratification 
at low disease activity (LDA) and remission thresholds (32.0% and 66.6% concordance respectively). Adjusting 
DAS28-CRP scores by gender significantly (p <0.001) improved agreement with the DAS28-ESR.  
 
Conclusion: Discordance between DAS28-ESR and DAS28-CRP is greatest for women and patients over 50 years 
of age, and influences disease activity stratification. The proposed gender adjusted DAS28-CRP improves inter-
score agreement with DAS28-ESR, supporting more reliable disease activity stratification in treat-to-target 
approaches for RA.  
Abstract Word Count: 181 
 
Key Messages: 
 This study shows that on average, DAS28-ESR generates scores 0.3 greater than the DAS28-CRP.  
 The difference between the DAS28-CRP and DAS28-ESR is greater for women and patients over 50. 
 Adjusting the DAS28-CRP according to gender significantly reduces inter-score differences with the 
DAS28-ESR. 
 
  
Introduction: 
 
Disease activity in rheumatoid arthritis (RA) is commonly measured using the 28-joint count disease activity 
score (DAS28), a composite index incorporating a tender joint count, swollen joint count, patient global 
assessment and markers of inflammatory response. The original DAS28 was developed and validated using the 
erythrocyte sedimentation rate (ESR) (1,2). Original development of the DAS28-CRP followed assessment of 
paired samples obtained from a relatively small cohort of 334 patients with subsequent wide adoption in clinical 
practice and trial settings (3). American College of Rheumatology (ACR) and European League Against 
Rheumatism (EULAR) do not differentiate between the two versions of the score when using disease activity 
thresholds. This results in the two versions of the score being used interchangeably in clinical practice (and 
observational studies which rely on data captured in clinical practice), with identical disease activity stratification 
thresholds adopted in assessment of disease activity, treatment response and treat-to-target approaches. 
Disparity in DAS28-CRP and DAS28-ESR values could also influence patient management where high-cost drug 
reimbursement is only permitted if specific disease activity thresholds are reached. In the UK access to biologics 
is dependent on patients having a DAS28 score of greater than 5.1 on two successive occasions at least one 
month apart (4). Therefore, discrepancies between scoring methods may delay the availability of biologic 
DMARDs to patients. Many studies have highlighted consistently lower DAS28-CRP compared to DAS28-ESR 
scores, at both lower levels of disease activity that form the focus of treat-to-target management (5-9) and high 
disease activity (10). It is acknowledged that ESR values are generally higher in females and increases with age 
(11), whilst the CRP is not affected by these factors. ESR and CRP levels may also be differentially affected by 
body mass index (BMI). Understanding the relative impact of gender, age and BMI on inter-score differences 
may help improve agreement between the DAS28-CRP and DAS28-ESR such that both instruments could be used 
interchangeably.  
 
We report an analysis from the British Society of Rheumatology Biologics Register for Rheumatoid Arthritis 
(BSRBR-RA) using real-world data, exploring discordance between the DAS28-CRP and DAS28-ESR, and resulting 
impact on disease activity stratification in RA. We propose that the DAS28-CRP should be adjusted depending 
on gender. 
 
Methods: 
Study population 
The BSRBR-RA is a national, prospective, longitudinal, observational study examining long-term safety of biologic 
agents in patients with RA in the UK. Ethical approval was obtained from the Multicentre Research Ethics 
Committee for the North-West of England. All patients enrolled provided written informed consent. 
Subject selection and data collection 
The methods of the BSRBR-RA have been described previously (12). Patients treated with biologic therapy with 
concurrent measures of ESR and CRP were identified from the BSRBR-RA, enabling paired calculation of DAS28-
ESR and DAS28-CRP using existing formulae (13). Data obtained at baseline and following treatment with 
biologic agents, was used in the initial cohort analysis. Data from patients taking tocilizumab were excluded due 
to specific effects of IL-6 on serum CRP levels (14).  
Statistical analysis 
The impact of age, baseline body mass index (BMI) and gender on concordance between DAS28-ESR and DAS28-
CRP was assessed by dichotomising the group for age (≥or< 50yrs), gender, and stratifying BMI according to 
World Health Organization thresholds (15). A random effects model was used to allow for the possibility that 
ESR and CRP were not measured from the same blood sample. Age at enrollment to the BSRBR-RA was used 
where it was not possible to calculate the age at time when the DAS28 score was measured. 
 
Agreement between the scores was compared using Bland-Altman statistics. Descriptive analysis was applied to 
compare disease stratification within accepted DAS28 disease activity thresholds. The cohort was subsequently 
subdivided according to gender. DAS28-CRP scores were differentially adjusted according to the inter-score 
differences identified in the initial analysis, and subsequent inter-score differences were compared. Kappa 
values and root mean squared error (RMSE) calculated the agreement and mean error of DAS28-CRP and 
subsequent adjusted DAS28-CRP scores (16). The differences in mean errors between the DAS28-ESR and 
DAS28-CRP or adjusted DAS28-CRP were compared using the Wilcoxon signed rank test. 
 
Results: 
Subject characteristics 
Paired ESR and CRP values were available for 8,509 subjects, with 31,074 paired assessments (Table 1). The 
majority of subjects were female (76%), with mean age of 57.3 years (SD 12.2) and a mean baseline disease 
duration of 12.7 years (SD 9.6).  
Discordance between DAS28-ESR and DAS28-CRP  
The DAS28-CRP was on average 0.3 points lower than the corresponding DAS28-ESR for the whole cohort.  When 
stratifying by age and gender, differences between the two scores were more pronounced for women and 
patients aged over 50 (0.35 points for both). The mean DAS28-CRP score in males was only 0.15 points less than 
the corresponding DAS28-ESR score. Mean inter-score differences did not alter when categorised by baseline 
BMI (Table 1Table 2).  
Impact of disparity between DAS28-ESR and CRP on disease activity stratification 
Disparity between the DAS28-ESR and DAS28-CRP had a significant impact on disease stratification, particularly 
within the low disease activity (LDA) category where the two scores only agreed in 32.0% of cases (Table 2Table 
3). The DAS28-ESR classified fewer patients in remission compared with the DAS28-CRP, and more in high 
disease activity  (Supplementary Table 1Table 2). 
Adjusting DAS28-CRP according to gender 
Subdividing the cohort by gender and adjusting DAS28-CRP scores by +0.35 for females and +0.15 for men 
significantly reduced inter-score differences overall (p <0.001 for females and males), and for age and BMI 
strata (Table 1Table 2). Inter-score disease activity classification improved for remission, low and moderate 
disease activities, with only a very minor reduction in agreement at high disease activity (3.9% and 0.7% for 
females and males respectively; Table 2Table 3). RMSE reduced from 0.62 to 0.51 DAS28 points for females 
and 0.58 to 0.56 for men and kappa was increased for females (from 0.61 to 0.69) and males (from 0.66 to 
0.69) when baseline DAS28-CRP scores were adjusted according to gender. 
 
Discussion: 
 
This study agrees with existing evidence suggesting DAS28-ESR and DAS28-CRP should not be viewed as 
interchangeable outcome measures, highlighting the limitations of doing so, with important consequences for 
clinical and research practice (5-10). We have proposed a novel and practical method for improving agreement 
between the two indices that could be applied in future observational studies and clinical practice where both 
methods have been applied at different time-points.  
 
Initial development of the DAS28-CRP by Fransen et al., which included data from 334 patients, used linear 
regression and high Pearson correlation coefficient to suggest equivalence with the DAS28-ESR. However, at 
that time, agreement analysis was not undertaken (3). Subsequent analyses by Wells et al. (17) demonstrated 
the DAS28-CRP to be a valid outcome measure, although inter-score discrepancies were identified. 
Consequently, whilst correlation between the scores was high, equivalence and interchangeability was not 
demonstrated. Disparity between DAS28-ESR and DAS28-CRP has led some to propose applying lower disease 
activity thresholds for the DAS28-CRP (6,7,10). However, this approach does not take into account the 
differential impact of age and gender between the two DAS28 scores. Furthermore, changing disease activity 
thresholds of the DAS28-CRP, would necessitate updating all guidance where reference is made only to the 
‘DAS28’ without specification as to the version used.   
 
We have demonstrated that variation in equivalence between the two scores is most pronounced for older 
patients and women (demographics representing the majority of the RA population) and at lower disease 
activity levels (the target for most treatment strategies). This discordance precludes easy comparison of 
outcomes of studies that have adopted different versions of the DAS28. The impact of BMI was lower than 
anticipated and correction for BMI to improve agreement between the two scores is not necessary. It is possible 
that other factors (including comorbidities) may affect the relationship between ESR and CRP measurements. 
However, limiting the additional data required to improve inter-score agreement means these findings can be 
translated to use in clinical and research settings. 
 
We propose that adjusting DAS28-CRP scores by +0.35 points for females and +0.15 points for males would 
significantly improve inter-score agreement, and allow existing disease activity thresholds to be used without 
modification. This adjustment takes into account observed biological differences in ESR levels between females 
and males and is straightforward and practical.  
 
Improvement in agreement of disease activity stratification at lower disease activity thresholds is achieved at 
the expense of a minor reduction in agreement at HDA; the effect of which would be to encourage more active 
treatment for patients with higher disease activity, in line with current treatment paradigms. Adjustment of the 
DAS28-CRP based on age was considered, however the time-varying nature of age makes this a less practical 
adjustment to the score. 
 
A potential limitation is that we used a single cohort for our study. However, patients included in the BSRBR-RA 
are enrolled from across the UK, representing a broad population and spectrum of RA management. The cohort 
is mainly of Caucasian ethnicity, which may influence ESR and CRP relationships differently compared with other 
ethnicities.(8,9) The main cohort included patients on biological agents recruited to a registry which may 
introduce selection bias, although it is unlikely this would impact on ESR/CRP comparisons. It is possible 
unknown confounders may influence whether an individual has both an ESR and CRP test undertaken rather 
than only one. There were some missing data, although there were no significant demographic differences 
between missing and complete groups (Supplementary Table 2Table 3).  
 
Our findings suggest the DAS28-ESR and DAS28-CRP should not be used interchangeably when stratifying 
disease activity. Gender influences inter-score agreement, and adjustment of the DAS28-CRP according to 
gender significantly improves inter-score reliability.  
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